Graves' disease in a patient with rheumatoid arthritis during treatment with anti-tumor necrosis factor-α

Journal of Rheumatology

Volumn 35, Issue 5, 2008, Pages 938-939

  Van Lieshout, Antoine W T ^a   Creemers, Marjonne C W ^a   Radstake, Timothy R D J ^a   Elving, Lammy D ^a   Van Riel, Piet L C M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTIBIOTIC AGENT; DISEASE MODIFYING ANTIRHEUMATIC DRUG; PROPRANOLOL; THIAMAZOLE; THYROTROPIN; THYROXINE;

AGED; CASE REPORT; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; GRAVES DISEASE; HUMAN; LETTER; PNEUMONIA; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; THYROID SCINTISCANNING;

AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; GRAVES DISEASE; HUMANS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 44349089200     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (12)

1. Maini R, St. Clair EW, Breedveld F, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999;354:1932-9.
2. Hyrich KL, Silman AJ, Watson KD, Symmons DP. Anti-tumour necrosis factor alpha therapy in rheumatoid arthritis: an update on safety. Ann Rheum Dis 2004;63:1538-43.
3. Mohan N, Edwards ET, Cupps TR, et al. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum 2001;44:2862-9.
4. Shakoor N, Michalska M, Harris CA, Block JA. Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet 2002;359:579-80.
5. Furst DE, Breedveld FC, Kalden JR, et al. Updated consensus statement on biological agents, specifically tumour necrosis factor-α blocking agents and interleukin-1 receptor antagonist, for the treatment of rheumatic diseases, 2005. Ann Rheum Dis 2005;64 Suppl:iv2-14.
6. Biro E, Szekanecz Z, Czirjak L, et al. Association of systemic and thyroid autoimmune diseases. Clin Rheumatol 2006;25:240-5.
7. Welsing P, Van Riel P, Fransen J, Kievit W. The relation of disease activity and methotrexate with the risk of cardiovascular disease in patients with rheumatoid arthritis [abstract]. In: Program, European League Against Rheumatism 2005 Annual Scientific Meeting; June 8-11, 2005; Vienna, Austria. Abstract OP0103.
8. Avunduk AM, Avunduk MC, Pazarli H, et al. Immunohistochemical analysis of orbital connective tissue specimens of patients with active Graves ophthalmopathy. Curr Eye Res 2005;30:631-8.
9. Celik I, Akalin S, Erbas T. Serum levels of interleukin 6 and tumor necrosis factor-alpha in hyperthyroid patients before and after propylthiouracil treatment. Eur J Endocrinol 1995;132:668-72.
10. Chopra IJ, Sakane S, Teco GN. A study of the serum concentration of tumor necrosis factor-alpha in thyroidal and nonthyroidal illnesses. J Clin Endocrinol Metab 1991;72:1113-6.
11. Diez JJ, Hernanz A, Medina S, Bayon C, Iglesias P. Serum concentrations of tumour necrosis factor-alpha (TNF-alpha) and soluble TNF-alpha receptor p55 in patients with hypothyroidism and hyperthyroidism before and after normalization of thyroid function. Clin Endocrinol 2002;57:515-21.
12. Paridaens D, van den Bosch WA, van der Loos TL, Krenning EP, van Hagen PM. The effect of etanercept on Graves' ophthalmopathy: a pilot study. Eye 2005;19:1286-9.